Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Biotechnology
The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece. 21 June 2019
Pharmaceutical
An Expert View on a burgeoning area that should tempt life science investors and professionals to leave their prejudice behind and take a closer look, from Jeannette VanderMarel, co-founder of The Green Organic Dutchman, the world’s largest organic cannabis producer, and chief executive of 48North Cannabis. 15 June 2019
Pharmaceutical
Patients must always be the center around which the entire innovation process revolves, while seeking to satisfy unmet patient needs, writes Alfredo Barón de Juan, Executive Vice President, Global Commercial Operations at Almirall, in an Expert View piece. 5 June 2019
Biotechnology
Investors stand to play a crucial role in driving healthcare sustainability as well as supporting scientific innovation, write Nathalie Flury and Michael Schröter, founding partners at Swiss asset manager Viopas Partners, and Kate Dion, healthcare value communications consultant at 3D Communications, in an Expert View piece. 24 May 2019
Pharmaceutical
Lithuania's new assessment procedure for reimbursable medicines: will there be any positive changes?
Lithuanian attorney Ruta Pumputiene provides an Expert View on amendments to the Lithuanian Pharmaceutical Law and the subsequent changes to the reimbursable medicines system. 15 May 2019
Pharmaceutical
Edward Jones, policy and communications consultant at GK Strategy, provides an Expert View on how companies can take advantage of the UK National Health Service's policy initiatives to support market access and uptake. 10 May 2019
Pharmaceutical
An Expert View column on how a valuable patent protection encourages development and helps to fund future battles provided by Robert Watson, partner, and Sarah Kostiuk-Smith, European patent attorney, from Mewburn Ellis. 8 May 2019
Pharmaceutical
In an Expert View piece, Oliver Kidd, senior associate at Stevens & Bolton, provides an overview of an ever-more complex landscape. 24 April 2019
Pharmaceutical
Professional investors are a fascinating group of individuals, enjoying an incredibly direct link between results and reward, so a lot can be learned from understanding how they focus effort, writes Brian McGee, partner at Novasecta, in an Expert View piece. 18 April 2019
Pharmaceutical
Pharma needs to pay closer attention to ensuring the integrity of its third-party relationships, writes Kathy Johnson, vice president life sciences, LexisNexis Risk Solutions Health Care, in an Expert View piece. 9 April 2019
Pharmaceutical
An Expert View on a growing trend among drug developers from Rik Van Mol, vice president of R&D strategy, Europe, Veeva Systems. 4 April 2019
Pharmaceutical
An Expert View looking at the key factors that will drive deal activity over the next year from Michael Jewell, partner, head of healthcare & life sciences at Cavendish Corporate Finance. 18 March 2019
Pharmaceutical
Even if the UK parliament votes against ‘no deal’ on Wednesday, in the wacky world of Brexit, this cliff-edge scenario is still possible – so Stevens & Bolton partner Charlotte Tillett and senior associate Paula Harris, consider the potential implications for pharma in an Expert View piece. 13 March 2019
Pharmaceutical
In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market: being under increasing pressure to expedite the development of new therapies, to decrease clinical study duration, and to drive new treatments through their clinical phases as quickly, safely and cost-efficiently as possible. 5 March 2019
Biotechnology
Aaron Hudson, vice president of marketing and clinical diagnostics, SCIEX, writes an expert view on the science that is often considered “closest to the phenotype”. 13 February 2019
Pharmaceutical
Amanda Powell-Smith, chief executive of Forster Communications, outlines the opportunities for pharma companies choosing to follow new guidance on the UK corporate governance framework. 4 February 2019
Pharmaceutical
Ahead of the Falsified Medicines Directive (FMD) coming into play in the European Union on February 9, Christian Taylor, Serialization Business Consultant at Zetes, provides his five-step plan to becoming FMD compliant in an Expert View piece. 25 January 2019
Pharmaceutical
Imogen Ireland, life sciences IP associate for law firm Hogan Lovells, raises some important issues relating to advances in artificial intelligence (AI) that drugmakers may not have fully considered, in an Expert View piece. 9 January 2019
Pharmaceutical
Does the way artificial intelligence is used in pharma need to be reimagined? Irina Efimenko, chief executive of Russian analytics experts Semantic Hub, and Mike Samsonov, chief medical officer of R-Pharm, consider this question in an Expert View piece. 20 December 2018
Biosimilars
Although biosimilars have taken off in Europe, they have yet to gain traction in the USA, writes Anne Runyan, senior consultant of market access at MKO Global Partners, in an Expert View on the topic. 11 December 2018
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International, and chair of the Medical Affairs Professional Society (MAPS) board. 29 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Biotechnology
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
Pharmaceutical
An Expert View from Adrienne Rivlin, a partner in LEK’s Healthcare practice. 19 April 2024
Pharmaceutical
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex. 4 April 2024
Biotechnology
An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson. 25 March 2024
Pharmaceutical
An Expert View from Rajan Jethwa, chief executive of Ellipses Pharma. 24 March 2024
Pharmaceutical
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
Pharmaceutical
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze